Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
ENLV Stock Chart & Stats
$0.95
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.95
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.66 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$225.99M
Enterprise Value$21.77M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta1.02
Next Earnings
May 22, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding237,381,500
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-65.57
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$13.00Price Target Upside1268.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Regulatory ProgressFDA IND clearance to run a global, randomized, placebo-controlled Phase 2b trial materially advances Allocetra from early proof-of-concept toward definitive efficacy data. This regulatory milestone reduces development pathway uncertainty, improves ability to attract partners, and strengthens long-term commercial potential in a large, aging OA market.
Large Treasury Asset PositionA multi‑billion dollar treasury provides structural optionality: it can back clinical funding, serve as collateral, and finance operations or strategic initiatives without immediate equity issuance. If monetized prudently, these assets can extend runway and give management flexibility to advance trials and negotiate partnerships.
Governance And Market-focus ActionsShareholder‑approved charter amendments and a move to concentrate U.S. market focus reflect strengthened corporate governance and streamlined regulatory exposure. Coupled with very low leverage, these changes reduce administrative complexity and legal friction, improving institutional investor accessibility and governance durability.
Bears Say
No Recurring Commercial RevenueThe company lacks recurring product sales and has effectively no revenue across multiple years, meaning core operations aren't self‑funding. Long‑term commercial viability hinges on successful late‑stage trials and commercialization or partner deals, leaving sustained business performance conditional on future clinical outcomes.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicate structural cash burn from R&D and trials. Over a multi‑month horizon this drives dependence on external financing, increases dilution risk or restrictive financings, and constrains strategic optionality unless operating cash flow moves positive or treasury assets are liquidated.
Earnings And Equity Volatility From Treasury GainsA large 2025 profit tied to unrealized digital‑asset appreciation produces earnings and equity swings unrelated to operating progress. This reliance on volatile treasury valuation impairs earnings quality, masks operational weakness, and exposes the balance sheet to crypto market and regulatory risk, complicating long‑term planning.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $225.99M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 22, 2026 which is in 46 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on Mar 25, 2026. The company reported -$0.086 earnings per share for the quarter, the consensus estimate of -$0.086 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate is -0.08.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 237,381,500 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.086 in its last earnings report, expectations of -$0.086. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (1268.42% Upside)
$13.00 (1268.42% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
-62.91%
Trailing 12-Months
Asset Growth
8304.66%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
$13.00
▲(1268.42% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.01% Other Institutional Investors
99.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---